Home / Themes / MedTech Long '25 : US Drug Dev Outsourcing
MedTech Long '25 : US Drug Dev Outsourcing (view performance)
Last updated
Theme thesis · 3/5 sections · Tickers 3 with notes · 5 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThis basket benefits from a structural shift toward U.S.-based drug development and biopharma supply chain reshoring, catalyzed by Trump 2.0's trade war posture
Thesis
This basket benefits from a structural shift toward U.S.-based drug development and biopharma supply chain reshoring, catalyzed by Trump 2.0's trade war posture, RFK's anti-China HHS stance, and increasing executive/federal aversion to China-based CRO/CDMO services. Even without the BIOSECURE Act passing, the regulatory and reputational risk of relying on offshore services has spurred U.S.-focused demand, contract wins, and capital investment across the domestic life sciences value chain.
Bull case
BIOSECURE Act failed but reshoring persists: U.S. firms are still redirecting preclinical and manufacturing work away from China to domestic providers like TKNO, NOTV, and FTRE despite the act not passing
Funding inflects off the bottom: Biopharma venture funding and pipeline activity have rebounded in early 2025, driving volume growth for U.S.-centric CRO/CDMOs across diagnostics and early-stage services
AI and organoid initiatives expand TAM: FDA support for AI and lab-based alternatives to animal testing (e.g. CERT, TKNO) is enhancing demand for domestic platforms with data and infrastructure advantages
Bear case
BIOSECURE failure signals policy fade: Without legislation, enforcement risks may ease and large pharma may delay or reverse onshoring investments.
China stimulus and cost arbitrage lure contracts back: Lower-cost Chinese providers may regain market share if political pressure eases or clients seek margin relief.
Capital expenditure slows in downturn: A broader market or biotech correction could delay infrastructure investments and contract volume for U.S.-based vendors.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| BIOSECURE-related policy changes or procurement bans | Event-driven | Identifies changes to contract eligibility or funding restrictions tied to China. | Google_Sheets |
| Domestic biopharma capex and facility investment | Quarterly/Annual | Tracks buildout of U.S. drug manufacturing and development capacity. | Google_Sheets |
| U.S.-only biopharma CRO/CDMO contract flow and RFPs | Quarterly | Measures whether sponsors are selecting domestic over offshore providers. | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| AVTR_c50e664b | by my anniversary (mid-August 2026) | 2026-07-22 | 2026-08-31 | Finalization of the senior leadership team restructuring, including the announcement of a new Chief Digital Officer, Chief Transformation Officer, and other high-impact leaders. | A fully formed and strengthened leadership team is essential for effectively executing the 'Revival' agenda and driving strategic initiatives across the organization. | Ticker | 2026-04-29 | earnings_transcript | AVTR (ticker) |